reports
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
DEME secures foundation and cable installation contracts for BC-Wind o...
DEME secures foundation and cable installation contracts for BC-Wind offshore wind farm in Poland DEME has been awarded three contracts for the installation of monopile foundations, inter-array cables, and the export cable at the BC-Wind offshore wind farm in Poland. These new contracts position DEME as a key contributor to Poland’s renewable energy build-out, supporting the country’s energy transition. Attachment
DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind...
DEME wint contracten voor funderings- en kabelinstallatie voor BC-Wind offshore windpark in Polen DEME heeft drie contracten gewonnen voor de installatie van monopile funderingen, inter-arraykabels en de exportkabel voor het BC-Wind offshore windpark in Polen. Deze nieuwe contracten positioneren DEME als een belangrijke speler in de uitbouw van hernieuwbare energie in Polen en ondersteunen de energietransitie van het land. Bijlage
- Tijs Hollestelle
DEME Group/Model update/BUY
We increase our FY25F EBITDA margin estimate from 18.4% to 20.2%. DEME aims for a 2025 EBITDA margin between 20% and 22%. We aim at the low end of the guidance because: (1) 1H25 profitability was impacted by a string of one-off effects (positive in Offshore Energy and negative in the Dredging & Infra division) which clouds our view on the underlying profitability trends; (2) the Fehmarnbelt project in Germany-Denmark (c.€700m scope DEME) is facing a considerable delay which has increased overall...
- Guy Sips
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
Dynamic Top Pick List How to start 2026?
How to start 2026? We have selected for the KBC Securities Dynamic Top Pick List 12 large-cap companies — AB InBev, Aedifica, Argenx, ASMi, Azelis, DEME, D'Ieteren, Shurgard, Sofina, Vopak, WDP, and Wolters Kluwer — along with 3 small and mid-cap names (under €1.5bn in market capitalization): Corbion, EVS, and IBA. So, going into 2026, we maintain a balanced approach in our Dynamic Top Pick List, featuring 8 cyclical and 6 defensive stocks, with a particular emphasis on value stocks that have b...
EVS EVS BROADCAST EQUIPMENT SA
DIE D'IETEREN SA
SOF SOFINA SA
ASM ASM INTERNATIONAL N.V.
IBAB ION BEAM APPLICATIONS SA
ROYAL VOPAK NV
AED AEDIFICA SA
CSM CORBION NV
ABI ANHEUSER-BUSCH INBEV SA/NV
ARGX ARGEN-X SE
WDP WAREHOUSES DE PAUW SCA
AZE AZELIS GROUP NV
DEME DEME GROUP NV
SHUR SHURGARD SELF STORAGE LIMITED
Agfa announces additional measures to adjust the cost base of its trad...
Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market December 4, 2025 – 7:45 a.m. CET Regulated information Agfa announces additional measures to adjust the cost base of its traditional film activities to the reality in the market Mortsel, Belgium – December 4, 2025 – 7:45 a.m. CET Agfa today announced that it plans to implement additional measures to adjust the cost base of its traditional film activities to the accelerated global market decline. These measures are an extension to the plan that was announced in Novem...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn tra...
Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt 4 december 2025 – 7:45 uur CET Gereglementeerde informatie Agfa kondigt bijkomende maatregelen aan om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de realiteit in de markt Mortsel, België – 4 december 2025 – 7u45 Agfa kondigde vandaag aan dat het van plan is bijkomende maatregelen te nemen om de kostenbasis van zijn traditionele filmactiviteiten aan te passen aan de versnelde achteruitgang van de wereldwijde markten. Deze...
- Guy Sips
- Michiel Declercq
- Wim Hoste
Local Champions Mid Cap Conference Book 11.12.2025
This conference book is your guide to our annual Local Champions Mid Cap Conference set to take place on Thursday, 11 December 2025 at our historic building at Grand Place in Brussels. This event offers the possibility to have one-on-one meetings and/or attend small group sessions with the top management and/or IR of the following companies: BARCO | BEKAERT | DECEUNINCK | DEME | EVS | IBA | JENSEN GROUP | MATERIALISE | ONTEX | PROXIMUS | RECTICEL | XFAB
- Guy Sips
- Hilde Van Boxstael
- Kristof Samoy
- Wim Hoste
- Wim Lewi
- Guy Sips
DEME Another record year is taking shape
DEME is a world leader in the specialised fields of dredging, marine infrastructure, solutions for the offshore energy market, and environmental works. DEME can build on nearly 150 years of know-how and experience and has fostered a pioneering approach throughout its history, being a front runner in innovation and new technologies. A major milestone in 2025 was DEME's acquisition of Havfram, an international offshore wind contractor based in Norway with around 50 employees. The deal carried an...
Results of the Votes of the Combined Shareholders’ General Meeting of...
Results of the Votes of the Combined Shareholders’ General Meeting of November 27, 2025 Daix (France), New York City (New York, United States), November 28, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), today announced the results of the votes of its Combined Shareholders’ Meeting. The Combined Shareholders' Meeting was held on Thursday November 27, 2025, at 9 a.m. at Hôtel Villa M, 24-30 Bd Pasteur,...
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réu...
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 27 novembre 2025 Daix (France), New York City (New York, Etats-Unis), le 28 novembre 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la stéatohépatite associée à un dysfonctionnement métabolique (« MASH »), annonce les résultats des votes de son Assemblée Générale Mixte. L’Assemblée Générale Mixte s’est tenue le jeudi 27 novembre 2025 à 9 heures à l'Hôtel Villa M – 24-30 Bd P...
Information relating to the stabilization activities carried out in th...
Information relating to the stabilization activities carried out in the context of its recent offering Daix (France), New York City (New York, United States), November 24, 2025 – Publication of information relating to the stabilization activities carried out in the context of the recent public offering of Inventiva (the "Company" or "Inventiva") in the United States (the "Offering") of 38,961,038 American Depositary Shares ("ADSs"), each representing one ordinary share of the Company with a nominal value of €0.01. As announced on 18 November 2025, the underwriters have exercised in full the...
Informations relatives aux activités de stabilisation menées dans le c...
Informations relatives aux activités de stabilisation menées dans le cadre de sa récente offre au public Daix (France), New York City (New York, États-Unis), le 24 novembre 2025 - Publication d'informations relatives aux activités de stabilisation menées dans le cadre de la récente offre au public d'Inventiva (la "Société" ou "Inventiva") aux États-Unis (l'"Offre") de 38.961.038 American Depositary Shares ("ADSs"), chacune représentant une action ordinaire de la Société, d'une valeur nominale de 0,01 euro. Comme annoncé le 18 novembre 2025, les teneurs de livre associés ont intégralement ex...
- Jacob Mekhael
Inventiva 9M25 results show all is on track
Inventiva reported 9M25 results which hold no surprises, and confirmed its recently updated cash runway guidance, which following the € 149m capital raise announced in November 2025, extends the company's runway to end of 1Q27 (previously end of 3Q26). This provides funding beyond the expected topline results from the phase 3 (NATiV3) trial of lanifibranor in MASH which are expected in 2H26. We update our model for the additional cash and shares (185m outstanding), as well as tweak some of our o...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Wim Lewi
Inventiva reports 2025 Third Quarter Financial Information¹
Inventiva reports 2025 Third Quarter Financial Information¹ Cash and cash equivalents at €97.6 million, and €24.7 million in short-term deposits2 as of September 30, 2025.Revenues of €4.5 million for the first nine months of 2025.Cash runway expected until the end of the first quarter of 20273, including net proceeds from the November 2025 public offering. Daix (France), New York City, (New York, United States), November 21, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapi...
Inventiva publie ses informations financières du 3ème trimestre 2025¹
Inventiva publie ses informations financières du 3ème trimestre 2025¹ Trésorerie et équivalents de trésorerie à 97,6 millions d’euros, et 24,7 millions d’euros en dépôts à court terme2 au 30 septembre.Chiffre d’affaires de 4,5 millions d’euros sur les neuf premiers mois de 2025.Horizon de trésorerie prévue jusqu’à la fin du premier trimestre 20273, incluant le produit net de l'offre au public réalisée en novembre 2025 Daix (France), New York City (New York, Etats-Unis), le 21 novembre 2024 – Inventiva (Euronext Paris and Nasdaq :IVA) (la « Société »), société biopharmaceutique spécialisée ...
- ING Helpdesk
- Guy Sips
- Jacob Mekhael
- Livio Luyten
- Wim Hoste
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.